“Cost-Effectiveness Analysis of Empagliflozin in the Treatment of Patients With Type 2 Diabetes and Established Cardiovascular Disease in Italy, Based on the Results of the EMPA-REG OUTCOME Study”. Farmeconomia. Health economics and therapeutic pathways 18, no. 1 (October 5, 2017). Accessed October 29, 2025. https://journals.seedstm.com/index.php/FE/article/view/1332.